SC 51089

structure in first source; dinoprostone antagonist

Also Known As:

SC-51089; SC51089; Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-(1-oxo-3-(4-pyridinyl)propyl)hydrazide, monohydrochloride

Networked: 12 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrazines: 379
  - SC 51089: 12
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azepines: 11
    - Oxazepines: 5
      - SC 51089: 12

Experts

1.	Zhou, Ping: 2 articles (01/2016 - 01/2009)
2.	Doré, Sylvain: 2 articles (12/2015 - 01/2014)
3.	Chang, L: 1 article (04/2018)
4.	Li, Q B: 1 article (04/2018)
5.	Luo, Q H: 1 article (04/2018)
6.	Shu, H H: 1 article (04/2018)
7.	Tao, Y X: 1 article (04/2018)
8.	Ye, F: 1 article (04/2018)
9.	Chiaia, Nicolas: 1 article (03/2016)
10.	Collins, Stuart A: 1 article (03/2016)

Related Diseases

1.	Brain Ischemia (Cerebral Ischemia) 12/09/2015 - "We found that post-ischemic treatment with the EP1 antagonist, SC-51089, or EP1 genetic deletion results in a significant reduction in BBB disruption and reduced hemorrhagic transformation in an experimental model of transient focal cerebral ischemia. " 01/01/2009 - "We investigated the preclinical characteristics of the neuroprotective effect of the prostaglandin E2 type 1 receptor (EP1) antagonist SC51089 in models of focal cerebral ischemia produced by occlusion of the mouse middle cerebral artery (MCA). " 08/25/2010 - "So we examined the effect of a prostanoid EP1 receptor antagonist, SC51089, on BBB leakage and tyrosine phosphorylation of occludin after cerebral ischemia. "
2.	Brain Injuries (Brain Injury) 01/01/2009 - "We found that systemic administration of SC51089 (5 to 20 microg/kg; i.p.) reduces the brain injury produced by transient (-50%+/-8%; n=12; P<0.05) or permanent (-39%+/-7%; n=12; P<0.05) MCA occlusion. " 01/01/2011 - "Consequently, in this study, we investigated the use of SC-51089, a selective prostaglandin E2 EP1 receptor antagonist, as a pre-treatment modality to decrease cell death, reduce brain edema, and improve neurobehavioral function after surgically induced brain injury (SBI) in mice. "
3.	Gliosis 01/01/2014 - "Immunohistochemistry studies revealed CCI-induced gliosis and microglial activation in selected ipsilateral brain regions that were not affected by SC-51089 or in the EP1 receptor-deleted mice. "
4.	Brain Edema (Cerebral Edema) 01/01/2011 - "Consequently, in this study, we investigated the use of SC-51089, a selective prostaglandin E2 EP1 receptor antagonist, as a pre-treatment modality to decrease cell death, reduce brain edema, and improve neurobehavioral function after surgically induced brain injury (SBI) in mice. "
5.	Hyperalgesia 04/01/2018 - "This hyperalgesia could be partly or totally prevented by the pretreatment of either parecoxib or SC51089. " 09/01/1994 - "Prostaglandin E1-induced hyperalgesia was not inhibited by E-type 1 prostaglandin receptor antagonists, SC19220 or SC51089, either in normal or diabetic rats. " 04/01/2018 - "The effects of the COX-2 inhibitor, parecoxib (intraperitoneal 10 mg kg-1), or the EP-1R antagonist, SC51089 (intraperitoneal 100 μg kg-1), on hyperalgesia and spinal PGE2 were examined. "

Related Drugs and Biologics

1.	Dinoprostone (PGE2)
2.	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
3.	Prostaglandins
4.	N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamide
5.	Occludin
6.	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)
7.	Neuroprotective Agents
8.	Prostaglandin E Receptors (Prostaglandin E Receptor)
9.	Misoprostol (Cytotec)
10.	Tyrosine (L-Tyrosine)